Zobrazeno 1 - 10
of 110
pro vyhledávání: ''
Autor:
Martin Treder, Michael Damrat, Torsten Haneke, Stefan Knackmuss, Susanne Wingert, Ute Schniegler-Mattox, Michael Tesar, Thomas Mueller, Michael Kluge, Wolfgang Fischer, Joachim Koch, Kristina Ellwanger, Ivica Fucek, Uwe Reusch, Jens Pahl, Erich Rajkovic
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Epidermal growth factor receptor (EGFR)-targeted cancer therapy such as anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors have demonstrated clinical efficacy. However, there remains a medical need addressing limitations of these therapie
Autor:
Xiaowu Liu, Xue Hu, Chunyin Gu, Zhiming Yuan, Xin Chen, Li Yu, Wuxiang Guan, Li Gao, Nan Li, Zhongzong Pan, Tianquan Hou, Su Jun Deng, Hong Liang, Congyi Yang, Xueyi Huang, Meng Shi, Fangfang Jia, Lu Yang, Yun Peng, Ge Gao, Kunpeng Liu, Donglin Song, Weiwei Guo, Zhen Chen, Chao Shan, Haixia Ma, Guoping Jiang, Yiwu Zhou, Zongda Wang, Xueping Wang, Jianjian Zhang, Yanan Li, Peipei Liu, Zheng Xiao, Yecheng Zhang, Juan Min, Guoqiao Lu, Xiaodan Cao, Yuting Wang, Yanfeng Yao, Weichen Liang, Kaiwen Xia, Jianhua Xue, Haibing Guo, Xiao Hu
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein during infection. After the virus se
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
The determination of concentrations of large therapeutic molecules, like monoclonal antibodies (mAbs), in the interstitial brain fluid (ISF) is one of the cornerstones for the translation from preclinical species to humans of treatments for neurodege
Publikováno v:
MAbs
Multivalent mono- or bispecific antibodies are of increasing interest for therapeutic applications, such as efficient receptor clustering and activation, or dual targeting approaches. Here, we present a novel platform for the generation of Ig-like mo
Autor:
Virginie McManus, James R. Apgar, Sonia Beyer, Sharon M. Campbell, Orla Cunningham, Matthew Allister Lambert, Joseph DeBartolo, Eric M. Bennett, Lydia Mosyak
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Despite substantial technological advances in antibody library and display platform development, the number of approved biotherapeutics from displayed libraries remains limited. In vivo, 20–50% of peripheral B cells undergo a process of receptor ed
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Immunoglobulin G-based monoclonal antibodies (mAbs) have become a dominant class of biotherapeutics in recent decades. Approved antibodies are mainly of the subclasses IgG1, IgG2, and IgG4, as well as their derivatives. Over the decades, the selectio
Autor:
Paul B. Harvilla, Ninkka Tamot, Adam Zwolak, Jason Ho, Matthew D. Truppo, Rajitha Doddareddy, Tong-Yuan Yang, M. Jack Borrok, Ian White, Chowdhury Partha, Qun Jiao, Rajkumar Ganesan, Brian Geist
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
The global health crisis and economic tolls of COVID-19 necessitate a panoply of strategies to treat SARS-CoV-2 infection. To date, few treatment options exist, although neutralizing antibodies against the spike glycoprotein have proven to be effecti
Autor:
Dorte Kornerup Ditlevsen, Annemette V. Thougaard, Karen Malene Wegener, Lone Fjord-Larsen, Frank Larsen, Lise Maj Schrøder-Hansen, Marianne Kaarde, Joan Christiansen
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Alpha-synuclein is a 15 kDa protein associated with neurodegenerative diseases such as Parkinson disease and multiple-system atrophy where pathological forms of alpha-synuclein aggregate and become neurotoxic. Here we describe the nonclinical program
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
A growing body of evidence supports the important role of molecular charge on antibody pharmacokinetics (PK), yet a quantitative description of the effect of charge on systemic and tissue disposition of antibodies is still lacking. Consequently, we h
Autor:
Zebin Wang, Sharon Lu, Simon Roberts, Hadi Danaee, Tamlyn Y. Neben, Sujatha Kumar, Marino Margaret Habash, Srimoyee Ghosh, Sridhar Ramaswamy, David Jenkins, Marilyn Kehry, Shouqi Luo, Geeta Sharma
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Inhibitors of programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have dramatically changed the treatment landscape for patients with cancer. Clinical activity of anti-PD-(L)1 antibodies has resulted in increased median overall survival and